H Locht1, K A Krogfelt. 1. Department of Autoimmunology, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark. hlo@ssi.dk
Abstract
OBJECTIVES: To estimate the incidence of postinfectious joint complaints after Campylobacter jejuni/coli enteritis compared with enteritis caused by enterotoxigenic E coli (ETEC). To compare gastrointestinal symptoms, antibiotic treatment, and antibody levels among patients with and without joint symptoms. METHOD: Questionnaires were sent to 210 consecutive patients with Campylobacter infection and an equal number of patients with E coli (ETEC). Blood samples for anti-Campylobacter antibodies were collected after two weeks, three months, six months, and two years. RESULTS: Twenty seven of 173 (16%) patients with Campylobacter and 10/177 (6%) with E coli (ETEC) reported joint symptoms (p=0.004). In the Campylobacter group duration of diarrhoea was a median of 13 days for patients with arthralgia and seven days for those without joint pain (p=0.0058). Patients with E coli had diarrhoea of longer duration than patients infected with Campylobacter (14 days v seven days; p=0.0005). E coli patients had fewer gastrointestinal symptoms than Campylobacter patients (p=0.0001). Fifty nine per cent of Campylobacter patients with joint pain had received antibiotic treatment because of enteritis compared with 26% with enteritis only (p=0.03). Campylobacter species and serotypes were equally distributed in both groups and there was no difference in anti-Campylobacter antibody levels between the groups. CONCLUSION: There was a significantly increased risk of developing joint symptoms after contracting Campylobacter infection compared with E coli. Campylobacter patients with joint pain had more severe gastrointestinal symptoms and longer duration of diarrhoea. Antibiotic treatment does not seem to prevent reactive joint symptoms. Levels of anti-Campylobacter antibodies were the same in both groups.
OBJECTIVES: To estimate the incidence of postinfectious joint complaints after Campylobacter jejuni/coli enteritis compared with enteritis caused by enterotoxigenic E coli (ETEC). To compare gastrointestinal symptoms, antibiotic treatment, and antibody levels among patients with and without joint symptoms. METHOD: Questionnaires were sent to 210 consecutive patients with Campylobacter infection and an equal number of patients with E coli (ETEC). Blood samples for anti-Campylobacter antibodies were collected after two weeks, three months, six months, and two years. RESULTS: Twenty seven of 173 (16%) patients with Campylobacter and 10/177 (6%) with E coli (ETEC) reported joint symptoms (p=0.004). In the Campylobacter group duration of diarrhoea was a median of 13 days for patients with arthralgia and seven days for those without joint pain (p=0.0058). Patients with E coli had diarrhoea of longer duration than patients infected with Campylobacter (14 days v seven days; p=0.0005). E coli patients had fewer gastrointestinal symptoms than Campylobacterpatients (p=0.0001). Fifty nine per cent of Campylobacterpatients with joint pain had received antibiotic treatment because of enteritis compared with 26% with enteritis only (p=0.03). Campylobacter species and serotypes were equally distributed in both groups and there was no difference in anti-Campylobacter antibody levels between the groups. CONCLUSION: There was a significantly increased risk of developing joint symptoms after contracting Campylobacter infection compared with E coli. Campylobacterpatients with joint pain had more severe gastrointestinal symptoms and longer duration of diarrhoea. Antibiotic treatment does not seem to prevent reactive joint symptoms. Levels of anti-Campylobacter antibodies were the same in both groups.
Authors: J Sieper; C Fendler; S Laitko; H Sörensen; C Gripenberg-Lerche; F Hiepe; R Alten; W Keitel; A Groh; J Uksila; U Eggens; K Granfors; J Braun Journal: Arthritis Rheum Date: 1999-07
Authors: M P Samuel; S H Zwillich; G T Thomson; M Alfa; K B Orr; D C Brittain; J R Miller; P E Phillips Journal: J Rheumatol Date: 1995-10 Impact factor: 4.666
Authors: Amit X Garg; Louise Moist; Douglas Matsell; Heather R Thiessen-Philbrook; R Brian Haynes; Rita S Suri; Marina Salvadori; Joel Ray; William F Clark Journal: CMAJ Date: 2005-05-27 Impact factor: 8.262
Authors: Ninell P Mortensen; Kelly A Mercier; Susan McRitchie; Tammy B Cavallo; Wimal Pathmasiri; Delisha Stewart; Susan J Sumner Journal: Biomed Microdevices Date: 2016-06 Impact factor: 2.838
Authors: Valérie R Louis; Iain A Gillespie; Sarah J O'Brien; Estelle Russek-Cohen; Andrew D Pearson; Rita R Colwell Journal: Appl Environ Microbiol Date: 2005-01 Impact factor: 4.792
Authors: Jennifer A Curry; Mark S Riddle; Robert P Gormley; David R Tribble; Chad K Porter Journal: BMC Infect Dis Date: 2010-09-13 Impact factor: 3.090